Reuters: Loss of Yasmin contraceptive patent knocks Bayer

[chris]

Loss of Yasmin contraceptive patent knocks Bayer
      

FRANKFURT (Reuters) - Shares in Bayer  slumped as much as 5.6 percent on Tuesday after a U.S. court voided a key patent on its Yasmin oral contraceptive drug, prompting the German group to tweak its healthcare margin goal.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login